A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 668-679

  Powers, John J ^a   Dubovsky, Jason A ^a   Epling Burnette, P K ^a   Moscinski, Lynn ^a   Zhang, Ling ^a   Mustjoki, Satu ^b   Sotomayor, Eduardo M ^a   Pinilla Ibarz, Javier A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic myelogenous leukemia; large granular lymphocytes; tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 15; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BB; TRANSCRIPTION FACTOR T BET;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTES; MALE; MIDDLE AGED; NF-KAPPA B; PROTEIN KINASE INHIBITORS; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 79953206281     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.550074     Document Type: Article

References (41)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up ofpatients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
2. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-123.
3. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
4. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010;16:338-347.
5. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366-1377. (Pubitemid 351213423)
6. Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition ofantigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14:2484-2491. (Pubitemid 351551084)
7. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008;111:4415-4416.
8. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008;127:330-339.
9. Wang H, Cheng F, Cuenca A, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005;105: 1135-1143. (Pubitemid 40170886)
10. Aswald JM, Lipton JH, Aswald S, Messner HA. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther 2002;7:143-149. (Pubitemid 37531602)
11. Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplanta-tion imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007;110: 4614-4617. (Pubitemid 351377831)
12. Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002;99:3861-3862. (Pubitemid 34534565)
13. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1009-1015. (Pubitemid 41741565)
14. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587-3592. (Pubitemid 26129585)
15. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.
16. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-782.
17. Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010;91:799-807.
18. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromo-some positive leukemia. Haematologica 2009;94:135-139.
19. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lym-phoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309-2315. (Pubitemid 47523149)
20. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814-818. (Pubitemid 47598483)
21. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914. (Pubitemid 47477268)
22. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008;141:745-747. (Pubitemid 351667633)
23. Chen X, Bai F, Sokol L, et al. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood 2009;113:3226-3234.
24. Zhang R, Shah MV, Yang J, et al. Network model ofsurvival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 2008;105:16308-16313.
25. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661. (Pubitemid 40053752)
26. Weisberg E, Manley PW, Breitenstein W, et al. Characteriza-tion of AMN107, a selective inhibitor ofnative and mutant Bcr-Abl. Cancer Cell 2005;7:129-141. (Pubitemid 40248339)
27. Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 2002;13:429-439. (Pubitemid 35303814)
28. Liew FY, McInnes IB. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 2002;61(Suppl. 2):ii100-ii102. (Pubitemid 35221730)
29. Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leuke-mia. Cancer Control 2009;16:141-152.
30. Kelley TW, Parker CJ. CD4 (+)CD25 (+)Foxp3 (+) regulatoryT cells and hematologic malignancies. Front Biosci (Schol Ed) 2010;2:980-992.
31. Li Y, Chen S, Yang L, et al. Clonal expanded TCR Vbeta T cells in patients with APL. Hematology 2005;10:135-139. (Pubitemid 41800787)
32. Raitakari M, Brown RD, Sze D, et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 2000;110:203-209. (Pubitemid 30625609)
33. Epling-Burnette PK, PainterJS, Rollison DE, et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007;21:659-667. (Pubitemid 46444549)
34. Kronenberg A, Seebach JD, Bossart W, Weber R. Polyclonal proliferation of large granular lymphocytes during cytomega-lovirus primary infection in a human immunodeficiency virus-infected patient receiving antiretroviral therapy. Clin Infect Dis 2001;33:E34-E36.
35. Smith PR, Cavenagh JD, Milne T, et al. Benign monoclonal expansion of CD8+ lymphocytes in HIV infection. J Clin Pathol 2000;53:177-181. (Pubitemid 30163598)
36. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013.
37. Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008;105:18895-18900.
38. Fraser CK, Blake SJ, Diener KR, et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009;37:256-265.
39. Tomlinson MG, Kane LP, Su J, Kadlecek TA, Mollenauer MN, Weiss A. Expression and function ofTec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec. Mol Cell Biol 2004;24:2455-2466. (Pubitemid 38326000)
40. Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartz-berg PL. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev 2009;228:93-114.
41. Lissina A, Ladell K, Skowera A, et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009;340:11-24.